Andy Chen
Stock Analyst at Wolfe Research
(4.47)
# 1,057
Out of 4,396 analysts
66
Total ratings
55.8%
Success rate
25.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Rated: Buy | $176 → $136 | $102.72 | +32.40% | 2 | Jun 3, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $88 | $31.81 | +176.64% | 4 | Jun 2, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $7 | $1.69 | +314.20% | 1 | Apr 8, 2026 | |
| AVTX Avalo Therapeutics | Initiated Coverage: Buy | $48 | $12.90 | +272.09% | 1 | Apr 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $98 | $84.57 | +15.88% | 1 | Apr 8, 2026 | |
| PHVS Pharvaris | Initiated Coverage: Buy | $42 | $31.60 | +32.91% | 1 | Apr 8, 2026 | |
| IMVT Immunovant | Maintained: Buy | $47 | $31.61 | +48.69% | 4 | Apr 6, 2026 | |
| CLDX Celldex Therapeutics | Upgraded: Buy | $51 → $44 | $29.60 | +48.65% | 3 | Mar 23, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgraded: Buy | $24 | $17.80 | +34.83% | 5 | Mar 23, 2026 | |
| APGE Apogee Therapeutics | Initiated Coverage: Hold | n/a | $85.02 | - | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $476.89 | - | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $548 | $445.77 | +22.93% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $76.91 | - | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $884.00 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.89 | - | 4 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.97 | +227.46% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $173 | $99.04 | +74.68% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $297.69 | - | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $15.89 | - | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $67.68 | -27.60% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $51.63 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $103.23 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $76.44 | n/a | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $66.93 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $34.97 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $18.42 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $16.31 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $58 | $74.58 | n/a | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $51.48 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $29.05 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $4.27 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0001 | n/a | 2 | Aug 10, 2023 |
ABIVAX Société Anonyme
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $102.72
Upside: +32.40%
Vera Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $88
Current: $31.81
Upside: +176.64%
Palisade Bio
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.69
Upside: +314.20%
Avalo Therapeutics
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $12.90
Upside: +272.09%
Dianthus Therapeutics
Apr 8, 2026
Maintained: Buy
Price Target: $98
Current: $84.57
Upside: +15.88%
Pharvaris
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $31.60
Upside: +32.91%
Immunovant
Apr 6, 2026
Maintained: Buy
Price Target: $47
Current: $31.61
Upside: +48.69%
Celldex Therapeutics
Mar 23, 2026
Upgraded: Buy
Price Target: $51 → $44
Current: $29.60
Upside: +48.65%
MoonLake Immunotherapeutics
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $17.80
Upside: +34.83%
Apogee Therapeutics
Jan 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $85.02
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $476.89
Upside: -
Jan 6, 2026
Upgraded: Buy
Price Target: $548
Current: $445.77
Upside: +22.93%
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $76.91
Upside: -
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $884.00
Upside: -
Nov 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $12.89
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $3.97
Upside: +227.46%
Aug 14, 2025
Maintained: Buy
Price Target: $54 → $173
Current: $99.04
Upside: +74.68%
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $297.69
Upside: -
Jun 16, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $15.89
Upside: -
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $67.68
Upside: -27.60%
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $51.63
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $84
Current: $103.23
Upside: n/a
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $76.44
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $66.93
Upside: n/a
Feb 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $34.97
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $18.42
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $16.31
Upside: n/a
Apr 9, 2024
Upgraded: Buy
Price Target: $58
Current: $74.58
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $51.48
Upside: n/a
Feb 14, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $29.05
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $4
Current: $4.27
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0001
Upside: n/a